GlassScriptPhysician profile
Michael Adrian Sims
NPI 1962990259
$3,656.02
in general payments reported to CMS, 2019-2025
28 companies · $1,454 in 2025
The $1,454 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $11.48 · 2021: $20.01 · 2023: $724 · 2024: $1,324 · 2025: $1,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085 · Education: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,085.26 |
| Education | $416.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $618.06 | 2023-2025 | Ensite, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $441.55 | 2024-2025 | Farxiga, Wainua, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.39 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $256.18 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $249.73 | 2023-2025 | Lifevest |
| Abiomed | $248.71 | 2024-2025 | Impella |
| Pfizer INC. | $201.32 | 2019-2025 | |
| Boston Scientific Corporation | $152.27 | 2024-2025 | Watchman Access System, Latitude Communicator Power Supply |
| Novo Nordisk INC | $150.97 | 2020-2024 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $149.48 | 2023-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $105.86 | 2023-2024 | |
| Amgen INC. | $90.53 | 2023 | Repatha |
| Janssen Pharmaceuticals, INC | $87.63 | 2023-2024 | Xarelto |
| Inspire Medical Systems, INC. | $87.39 | 2024-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $84.08 | 2023-2025 | Uptravi, Opsumit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procyrion, INC. | $75.10 | 2024-2025 | Aortix System |
| Regeneron Healthcare Solutions, INC. | $68.18 | 2025 | Evkeeza |
| Merck Sharp & Dohme LLC | $52.71 | 2025 | Verquvo |
| United Therapeutics Corporation | $50.45 | 2024-2025 | Tyvaso, Tyvaso |
| Alnylam Pharmaceuticals INC. | $45.88 | 2025 | Amvuttra |
| Bridgebio Pharma, INC. | $21.53 | 2025 | Attruby |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.01 | 2021 | |
| Livanova USA, INC. | $19.66 | 2023 | Tandemlife |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Medtronic, INC. | $18.08 | 2023 | Cobalt Dr Mri Surescan |
| Chiesi USA, INC. | $16.39 | 2023 | Kengreal, Cleviprex |
| Edwards Lifesciences Corporation | $13.92 | 2024 | Sapien 3 Ultra Resilia |
| Biotronik INC. | $13.34 | 2023 | Renamic Neo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.